Strategic Application of In Vitro Assays in Advancing Biotherapeutics for ADC, TCE, and Autoimmune Diseases

Dr. Macy Jin, MD,
Director, CRO Services at WuXi Biologics

Strategic Application of In Vitro Assays in Advancing Biotherapeutics for ADC, TCE, and Autoimmune Diseases

Click to play video

In vitro assays play a central role in biotherapeutic drug development by enabling critical insights into target identification, mechanism of action, and safety profiling. This presentation will provide an in-depth exploration of strategic application of in vitro assays through real-world case studies, illustrating their essential role in optimizing lead selection, assessing risks, and advancing drug candidates in ADC, TCE and autoimmune diseases therapeutics.

Speaker

Dr. Macy Jin, MD,
Director, CRO Services at WuXi Biologics

Macy Jin joined WuXi Biologics in April 2023 as a subject matter expert in Biotherapeutic Drug Discovery. Previously, she spent over 20 years at Wyeth/Pfizer, progressing from individual contributor to display platform group leader and project team leader in antibody discovery across oncology, autoimmune, and rare diseases. Macy brings extensive technical expertise, with 10 years in hybridoma and over 10 years in display-based antibody discovery technologies. She led phage panning and screening strategies to isolate Marsticimab (Hympavzi), FDA-approved in 2024 as the first anti-TFPI antibody for Hemophilia.